title: Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors.
abstract: OBJECTIVE
  The purpose of this study was to evaluate baseline RRM2 protein and gene expression in tumors of patients receiving 3-AP.
  
  
  METHODS
  Tumor blocks from patients enrolled in phase I and II clinical studies using 3-AP, were evaluated for RRM2 gene and protein expression by quantitative real time polymerase chain reaction (Q-RTPCR) and automated quantitative analysis (AQUA).
  
  
  RESULTS
  Esophageal and gastric cancers overexpressed RRM2 protein when compared to prostate cancer (Z-score, 0.68 +/- 0.94 SD, vs 0.41 +/- 0.84 SD, respectively; p = 0.04). Esophageal and gastric cancers also overexpressed RRM2 mRNA when compared to prostate cancer (relative gene expression 2.56 +/- 1.49 SD, vs 0.29 +/- 0.20 SD, respectively; p = 0.02). Protein and gene expression were moderately associated (Spearman's rank correlation = 0.30; p = 0.12).
  
  
  CONCLUSIONS
  RRM2 gene and protein expression varies by tumor type.
authors.affiliation: University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, WI 53792, USA. jmkolesar@pharmacy.wisc.edu
authors.forename: Jill
authors.initials: J
authors.lastname: Kolesar
authors.forename: Wei
authors.initials: W
authors.lastname: Huang
authors.forename: Jens
authors.initials: J
authors.lastname: Eickhoff
authors.forename: Kristine
authors.initials: K
authors.lastname: Hahn
authors.forename: Dona
authors.initials: D
authors.lastname: Alberti
authors.forename: Steven
authors.initials: S
authors.lastname: Attia
authors.forename: William
authors.initials: W
authors.lastname: Schelman
authors.forename: Kyle
authors.initials: K
authors.lastname: Holen
authors.forename: Anne
authors.initials: A
authors.lastname: Traynor
authors.forename: Percy
authors.initials: P
authors.lastname: Ivy
authors.forename: George
authors.initials: G
authors.lastname: Wilding
mesh_terms: D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D004938:Esophageal Neoplasms / Q000188:drug therapy / Q000235:genetics; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D016133:Polymerase Chain Reaction; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000235:genetics; D021122:Protein Subunits; D011725:Pyridines / Q000494:pharmacology*; D012333:RNA, Messenger / Q000378:metabolism*; D012262:Ribonucleoside Diphosphate Reductase / Q000235:genetics / Q000378:metabolism*; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000235:genetics; D013882:Thiosemicarbazones / Q000494:pharmacology*
chemical_list: D021122:Protein Subunits; D011725:Pyridines; D012333:RNA, Messenger; D013882:Thiosemicarbazones; C078157:3-aminopyridine-2-carboxaldehyde thiosemicarbazone; C093713:ribonucleotide reductase M2; D012262:Ribonucleoside Diphosphate Reductase